Nizatidine
Mechanism :
Competitive inhibition of histamine at H2-receptors of the gastric parietal cells, thus inhibits gastric acid secretion.
Indication :
- Duodenal ulcer
- Benign Gastric ulcer
- Gastroesophageal reflux disease
Contraindications :
Hypersensitivity to nizatidine, other H2 antagonists, or any component of the formulation.
Dosing :
GERD:
≥12 years
150 mg PO twice daily for up to 8 weeks. Maximum: 300 mg/day.
6 months-11 years (off-label use)
5-10 mg/kg/day PO in divided doses twice daily for up to 8 weeks.
Adverse Effect :
Headache, anxiety, dizziness, pruritus, skin rash, abdominal pain, anorexia, constipation, diarrhea, flatulence, cough, nasal congestion, fever.
Interaction :
Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime.
Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir.
Ketoconazole, Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of ketoconazole, itraconazole.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | 150–300 mg daily |
| <20 | 150 mg daily |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Not dialysed. Dose as in GFR<20 mL/min |
| HD | Not dialysed. Dose as in GFR<20 mL/min |
| HDF/High flux | Unknown dialysability. Dose as in GFR<20 mL/min |
| CAV/VVHD | Unknown dialysability. Dose as in GFR<20 mL/min |
Hepatic Dose :
No dose adjustments are recommended.